Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- None.
- None.
Insights
The approval of HYQVIA®, co-formulated with Halozyme's ENHANZE® drug delivery technology, by the European Commission for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) represents a significant milestone for Halozyme Therapeutics. This development is poised to have a substantial impact on the company's market presence in Europe, as the centralized marketing authorization allows access to all EU member states and select additional countries. It's important to note that CIDP is a rare autoimmune disorder affecting the peripheral nerves and the availability of new treatment options can significantly improve patient outcomes.
From a medical research perspective, the use of hyaluronidase in facilitating subcutaneous infusion could offer a less invasive and more convenient option compared to traditional intravenous methods, potentially leading to improved adherence and patient satisfaction. This could translate into a competitive advantage for Halozyme in the rare disease treatment market. Moreover, the ability for self-administration after training may reduce healthcare costs and increase accessibility for patients.
Halozyme's strategic partnership with Takeda to distribute HYQVIA® in Europe could significantly enhance its revenue streams and strengthen its position within the biopharmaceutical sector. The demand for personalized maintenance treatments in rare diseases like CIDP is growing and Halozyme's ENHANZE® technology is at the forefront of this trend. The technology's ability to enable subcutaneous delivery of biologics, which traditionally required intravenous administration, could disrupt the market by offering a differentiating factor that may appeal to both patients and healthcare providers.
For investors, this approval could be seen as a positive signal for Halozyme's growth potential and market expansion capabilities. However, it is also crucial to monitor the adoption rate of HYQVIA® in the new markets, the competitive landscape and the potential impact of healthcare policies on treatment accessibility and reimbursement.
The European Commission's approval of HYQVIA® introduces a new revenue stream for Halozyme in a market that has been showing increasing interest in advanced therapies for chronic conditions. This regulatory milestone could be a catalyst for stock performance, as market expansion often leads to increased sales and potentially enhances investor confidence in the company's growth trajectory. The long-term financial implications hinge on the successful commercialization and market penetration of HYQVIA® across Europe.
It's paramount to assess the potential market size for CIDP treatments in Europe and the pricing strategy that Halozyme will adopt. The company's ability to negotiate favorable reimbursement terms with European healthcare systems will be a critical factor in determining the financial success of the product. Additionally, investors should consider the operational costs associated with the market rollout and the impact of currency fluctuations on international revenues.
HYQVIA® is the only FDA and now EC-approved combination of immunoglobulin (IG) and hyaluronidase for CIDP and is administered by facilitated subcutaneous infusion. For patients with CIDP, HYQVIA® can be infused up to once monthly (every two, three or four weeks). HYQVIA® can be administered by a healthcare professional or self-administered in the patient's home after appropriate training.
"The demand for new personalized maintenance treatment options for patients with CIDP continues to grow, and we are pleased to partner with Takeda to expand the HYQVIA offering to
The centralized marketing authorization for HYQVIA® in CIDP is valid in all EU member states as well as in
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including Hylenex® and XYOSTED® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's ENHANZE® drug delivery technology including the possible benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery and certain other benefits of ENHANZE® including lowering the treatment burden for patients and alleviating pressure on health care system resources, including potential out-of-hospital administration of HYQVIA® . Forward-looking statements regarding the Company's ENHANZE® business may include potential growth driven by our partners' development and commercialization efforts (including anticipated regulatory submissions, PDUFA dates, potential regulatory approvals, indications and product launches). These forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected results or delays in the growth of the Company's business, or in the development, regulatory review or commercialization of the Company's partnered products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
617-877-9710
samantha.gaspar@teneo.com
References:
European Medicines Agency. HyQvia product information.
HYQVIA® [Immune Globulin Infusion
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-announces-takeda-received-european-commission-approval-for-hyqvia-co-formulated-with-enhanze-as-maintenance-therapy-for-chronic-inflammatory-demyelinating-polyneuropathy-cidp-302047182.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
What is the European Commission (EC) approval for HYQVIA®?
What is the FDA approval for HYQVIA®?
How is HYQVIA® administered?
Where is the centralized marketing authorization for HYQVIA® in CIDP valid?
